Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients

BACKGROUND - There is inconsistent information about the clinical usefulness of circulating cell-free DNA (cfDNA) in plasma from clear cell renal cell cancer (RCC) patients. This is attributed to preanalytical, analytical, and clinical factors that were considered as far as possible in this study.

METHODS - cfDNA was extracted from EDTA plasma of healthy people (n=40), non-metastatic (n=145) and metastatic (n=84) RCC patients using the QIAamp Circulating Nucleic Acid Kit. Genomic and mitochondrial cfDNA concentrations were determined using qPCR of different cfDNA fragments (67-306bp). Their diagnostic and prognostic potential was estimated using receiver operating characteristics (ROC) and Cox regression analyses.

RESULTS - The 67bp and 180bp genomic cfDNA fragments did not differ between the three study groups while the 306bp fragment was lower in RCC patients than in controls. The mitochondrial cfDNA was higher in metastatic than in non-metastatic patients and controls. The cfDNA integrity indices decreased from controls to metastatic patients. Models built by logistic regression and Cox regression resulted in area under the ROC curves >0. 75 and concordance indices of >0. 800 in predicting recurrence-free survival and overall survival.

CONCLUSIONS - The study suggests that combinations of cfDNA markers have promising diagnostic and prognostic potential in RCC patients and are worth for further validation in future prospective multicenter studies.

Clinica chimica acta; international journal of clinical chemistry. 2015 Nov 10 [Epub ahead of print]

Hongbiao Lu, Jonas Busch, Monika Jung, Silke Rabenhorst, Bernhard Ralla, Ergin Kilic, Steffen Mergemeier, Nils Budach, Annika Fendler, Klaus Jung

Department of Urology, University Hospital Charité, Berlin, Germany; Berlin Institute for Urological Research, Berlin, Germany; Department of Urology, Changzhou No. 2 People's Hospital, Jiangsu, China. , Department of Urology, University Hospital Charité, Berlin, Germany. , Department of Urology, University Hospital Charité, Berlin, Germany. , Department of Urology, University Hospital Charité, Berlin, Germany. , Department of Urology, University Hospital Charité, Berlin, Germany. , Institute of Pathology, University Hospital Charité, Berlin, Germany. , CONGEN Biotechnologie GmbH, Berlin, Germany. , Department of Radiology, University Hospital Charité, Berlin, Germany. , Department of Urology, University Hospital Charité, Berlin, Germany; Berlin Institute for Urological Research, Berlin, Germany; Department of Signal Transduction, Invasion and Metastasis of Epithelial Cells, Max Delbrück Center of Molecular Medicine, Berlin, Germany. , Department of Urology, University Hospital Charité, Berlin, Germany; Berlin Institute for Urological Research, Berlin, Germany.  

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe